Phase 4 Pulmonary Hypertension Trial, Recruiting (NCT05213676)

Phase 4 Pulmonary Hypertension Trial, Recruiting NCT05213676 Sponsor: The University of Texas Health Science Center, Houston Condition: Pulmonary Hypertension

Printed from Voxsanity (voxsanity.com.au) — NCT05213676 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pulmonary Hypertension

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Newborns who are born alive and diagnosed with a type of diaphragmatic hernia called a Bochdalek hernia (located on either the left or right side of the diaphragm)
Babies who have other additional health conditions or abnormalities alongside the hernia may still be considered for inclusion
Babies diagnosed with this condition before they are 1 month old
Babies who were born at, or transferred to, a participating study center within the first week of life

Who may not be able to join:

Babies who are not diagnosed with the hernia until after 1 month of age
Babies who have a Morgagni hernia, which is a different type of diaphragmatic hernia located at the front and center of the diaphragm
Babies who were transferred to a participating study center after the first week of life
Babies for whom the treating medical team does not have access to a specific inhaled medication called iNO (inhaled nitric oxide) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Matthew Harting, MD, MS, FACS, The University of Texas Health Science Center, Houston

Phone: (713) 500-7398

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05213676

Sponsor: The University of Texas Health Science Center, Houston

Phase: Phase 4

Status: Recruiting

Condition: Pulmonary Hypertension

Trial contact: (713) 500-7398

More information: https://clinicaltrials.gov/study/NCT05213676

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Newborns who are born alive and diagnosed with a type of diaphragmatic hernia called a Bochdalek hernia (located on either the left or right side of the diaphragm)
Babies who have other additional health conditions or abnormalities alongside the hernia may still be considered for inclusion
Babies diagnosed with this condition before they are 1 month old
Babies who were born at, or transferred to, a participating study center within the first week of life

Who may not be able to join:

Babies who are not diagnosed with the hernia until after 1 month of age
Babies who have a Morgagni hernia, which is a different type of diaphragmatic hernia located at the front and center of the diaphragm
Babies who were transferred to a participating study center after the first week of life
Babies for whom the treating medical team does not have access to a specific inhaled medication called iNO (inhaled nitric oxide) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

The University of Texas Health Science Center, Houston

Registry

ClinicalTrials.gov

Start date

1 November 2025

Est. completion

31 October 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants who require Extracorporeal Life Support (ECLS) and/or who die prior to discharge

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov